Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WU-CART-007 |
Synonyms | |
Therapy Description |
WU-CART-007 are allogeneic T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets CD7, potentially resulting in killing of tumor cells expressing CD7 and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 2772). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WU-CART-007 | WU-CART 007|WU-CART007 | WU-CART-007 are allogeneic T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets CD7, potentially resulting in killing of tumor cells expressing CD7 and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 2772). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05377827 | Phase I | WU-CART-007 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT04984356 | Phase Ib/II | WU-CART-007 | A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL | Completed | USA | NLD | FRA | AUS | 0 |